Catalog No.
VQJ05001
Species reactivity
Dog
Host species
Dog
Isotype
IgG2, kappa
Clonality
Monoclonal
Target
IL-31, Interleukin-31, IL31
Concentration
2.9 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
C7G0W1
Applications
ELISA, Neutralization
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Iv0213
Long-term use of lokivetmab in dogs with atopic dermatitis., PMID:39143659
Exploring the Potentiality of a Plant Platform for Monoclonal Antibody Production in Veterinary Medicine., PMID:38932349
Correlation between clinical efficacy on pruritus and serum interleukin-31 levels in dogs with atopic dermatitis treated with lokivetmab., PMID:37389418
Cytokine transcriptome profiling in acute experimental canine atopic dermatitis skin lesions after IL-31 inhibition with lokivetmab., PMID:37006124
Laboratory safety evaluation of lokivetmab, a canine anti-interleukin-31 monoclonal antibody, in dogs., PMID:36842258
Use of Cytopoint in the Allergic Dog., PMID:35928119
Development and characterization of a novel mouse anti-canine oncostatin M receptor beta monoclonal antibody., PMID:35576682
Lokivetmab improved pruritus in a dog with cutaneous epitheliotropic lymphoma., PMID:34866072
A masked, randomised clinical trial evaluating the efficacy and safety of lokivetmab compared to saline control in client-owned dogs with allergic dermatitis., PMID:34180084
Onset and duration of action of lokivetmab in a canine model of IL-31 induced pruritus., PMID:33830571
Evaluation of the cutaneous expression of IL-17, IL-22, IL-31, and their receptors in canine atopic dermatitis., PMID:33588097
Combined IMIG and Immune Ig Attenuate Allergic Responses in Beagle Dogs., PMID:32377529
Alterations in circulating concentrations of IL-17, IL-31 and total IgE in dogs with atopic dermatitis., PMID:31218782
Lokivetmab therapy for pruritus in a dog with cutaneous mastocytosis., PMID:30479052
A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA., PMID:30141223
Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis., PMID:28670717
Cockroach allergen exposure and plasma cytokines among children in a tropical environment., PMID:28668242
A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis., PMID:27647569
A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis., PMID:27647513
Interleukin (IL) 31 induces in cynomolgus monkeys a rapid and intense itch response that can be inhibited by an IL-31 neutralizing antibody., PMID:27501029
For research use only. Not for human or drug use.
